Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis

Abstract Introduction Patients with ankylosing spondylitis (AS) have significant unmet treatment needs, despite advancements in biologic therapies. This study evaluated the impact of upadacitinib on clinically meaningful improvement in patient-reported outcomes (PROs) assessing disease activity, pai...

Full description

Bibliographic Details
Published in:	Rheumatology and Therapy
Main Authors:	Victoria Navarro-Compán, Xenofon Baraliakos, Marina Magrey, Andrew Östör, Christopher D. Saffore, Manish Mittal, In-Ho Song, Fabiana Ganz, Jayne Stigler, Atul Deodhar
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2023-02-01
Subjects:	Ankylosing spondylitis Axial spondyloarthritis Patient-reported outcomes Health-related quality of life Upadacitinib
Online Access:	https://doi.org/10.1007/s40744-023-00536-2

Similar Items

Upadacitinib for the treatment of radiographic axial spondyloarthritis — case series and review of the literature
by: Giuseppe Lopalco, et al.
Published: (2025-05-01)

Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks
by: Helena Marzo-Ortega, et al.
Published: (2020-08-01)

A Real-World Comparison of Clinical Effectiveness of Upadacitinib, Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis After Switching from an Initial Tumor Necrosis Factor Inhibitor Treatment
by: Xenofon Baraliakos, et al.
Published: (2025-07-01)

Malignancy in ankylosing spondylitis: a cross-sectional analysis of a large population database
by: Mohamad Bittar, et al.
Published: (2022-06-01)

Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis
by: Jessica A. Walsh, et al.
Published: (2023-08-01)

CLINICAL EXPERIENCE WITH ETANERCEPT IN THE TREATMENT OF PATIENTS WITH ANKYLOSING SPONDYLITIS
by: O. A. Rumyantseva, et al.
Published: (2018-05-01)

Ankylosing Spondylitis
by: Nazanin Ebrahimiadib, et al.
Published: (2021-07-01)

Case Report: The combination of upadacitinib and adalimumab in the treatment of refractory ankylosing spondylitis
by: Jiajia Wu, et al.
Published: (2025-08-01)

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study
by: Xenofon Baraliakos, et al.
Published: (2024-11-01)

Advices for diagnostics of ankylosing spondylitis / axial spondyloarthritis: A review Part 2. Spinal column involvement
by: Nikolay V. Bunchuk, et al.
Published: (2024-05-01)

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials
by: Gerd R. Burmester, et al.
Published: (2024-04-01)

Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis
by: Qi Yao, et al.
Published: (2025-02-01)

Specific features of axial spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, in persons of different genders
by: A. P. Rebrov, et al.
Published: (2015-03-01)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
by: Xenofon Baraliakos, et al.
Published: (2023-09-01)

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis
by: Victoria Navarro-Compán, et al.
Published: (2024-05-01)

COMPARATIVE EVALUATION OF PATIENTS WITH ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
by: I. А. Cherentsova, et al.
Published: (2016-09-01)

Therapeutic Targets for Ankylosing Spondylitis – Recent Insights and Future Prospects
by: Perrotta FM, et al.
Published: (2022-04-01)

Ankylosing spondylitis: how does it affect the quality of life?
by: Eva Perak, et al.
Published: (2023-01-01)

Anti-CD74 IGA antibodies, genetic polymorphisms and inflammatory activity in ankylosing spondylitis
by: V. I. Mazurov, et al.
Published: (2021-01-01)

Advices for diagnostics of ankylosing spondylitis/axial spondyloarthritis: A review
by: Nikolay V. Bunchuk, et al.
Published: (2023-11-01)

Remission in ankylosing spondylitis and axial spondyloarthritides: A modern understanding of the problem
by: I. Z. Gaydukova, et al.
Published: (2016-03-01)

IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?
by: Dominique Baeten, et al.
Published: (2021-02-01)

THE NEED AND POSSIBILITIES OF EARLY DIAGNOSIS OF ANKYLOSING SPONDYLITIS: COMMENTARIES ON THE PAPER «EARLY DIAGNOSIS OF ANKYLOSING SPONDYLITIS» (No. 4, 2013) AND DISCUSSION IN THE JOURNAL (No. 2, 2014)
by: Sh. F. Erdes
Published: (2014-09-01)

Features of ankylosing spondylitis at different stages in men and women
by: I. A. Cherentsova, et al.
Published: (2019-05-01)

The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study
by: Jie Chang, et al.
Published: (2024-01-01)

Probiotics in Ankylosing Spondylitis: A Possible Potency
by: Sumartini Dewi, et al.
Published: (2020-07-01)

Ankylosing spondylitis morbidity trends in Russia and Saturday spondyloarthritis schools
by: Shandor Fedorovich Erdes, et al.
Published: (2013-04-01)

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA
by: V. I. Mazurov, et al.
Published: (2020-11-01)

Disease activity and functional outcomes in non-radiographic spondyloarthritis versus ankylosing spondylitis – preliminary results
by: Ana-Maria Doca, et al.
Published: (2022-09-01)

Clinical trial landscape for ankylosing spondylitis: Current insights and future innovations
by: Hui Li, et al.
Published: (2024-10-01)

Comparison of Ankylosing Spondylitis Disease Activity Score and Bath Ankylosing Spondylitis Disease Activity Index tools in assessment of axial spondyloarthritis activity
by: Katarzyna Małgorzata Wiąk-Walerowicz, et al.
Published: (2024-03-01)

Diffuse idiopathic skeletal hyperostosis and axial spondyloarthritis—similarities and differences
by: David Kiefer, et al.
Published: (2023-11-01)

The incidence and prevalence of ankylosing spondylitis in Thailand using ministry of public health database
by: Ajanee Mahakkanukrauh, et al.
Published: (2024-07-01)

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
by: Filip Van den Bosch, et al.
Published: (2025-02-01)

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
by: Xenofon Baraliakos, et al.
Published: (2023-04-01)

LABORATORY BIOMARKERS FOR ANKYLOSING SPONDYLITIS
by: E. N. Aleksandrova, et al.
Published: (2017-03-01)

Multi ‘Omics Analysis of Intestinal Tissue in Ankylosing Spondylitis Identifies Alterations in the Tryptophan Metabolism Pathway
by: Adam J. Berlinberg, et al.
Published: (2021-03-01)

The Role of Imaging in Diagnosing Axial Spondyloarthritis
by: Nikita Khmelinskii, et al.
Published: (2018-04-01)

A case of ankylosing spondylitis presenting with fever of unknown origin diagnosed as aortitis: A case report
by: Mahsa Mehdipour Dalivand, et al.
Published: (2023-11-01)

TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS
by: S. A. Lapshina, et al.
Published: (2016-09-01)